Neos Therapeutics

What Neos Therapeutics does

Neos Therapeutics was a specialty pharmaceutical company built around proprietary oral drug delivery technology, most notably controlled-release and orally disintegrating tablet (ODT) formulations used in branded central nervous system (CNS) therapeutics. Its commercial franchise was anchored on ADHD treatments including Adzenys XR-ODT and Cotempla XR-ODT, serving pediatric and adolescent patients along with the broader ADHD population. The company was originally founded in 2008, headquartered in Grand Prairie, Texas, and listed on NASDAQ under the ticker NEOS before being acquired by Aytu BioPharma (NASDAQ: AYTU) in 2021, ending Neos's standalone operations.

Following the acquisition, Neos's ADHD portfolio was integrated into Aytu's broader CNS-focused pharmaceutical platform, headquartered in Denver, Colorado. The combined entity (Aytu BioPharma, employing 51–100 people) markets three product lines today: the Neos-derived ADHD Portfolio, a Pediatric Portfolio, and EXXUA™, a novel therapeutic for major depressive disorder (MDD) launched in 2025. Revenue is generated through traditional pharmaceutical commercialization: direct distribution to healthcare providers and pharmacies, supported by the RxConnect patient access program. Neos's drug delivery IP and branded product assets remain the foundation of the ADHD franchise within the parent platform.

Name

Neos Therapeutics

Legal name

Aytu BioPharma

Website

https://neostx.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Neos Therapeutics was an oral drug delivery pharmaceutical company that developed controlled-release and orally disintegrating tablet ADHD treatments; acquired by Aytu BioPharma in 2021, its ADHD portfolio now anchors Aytu's CNS franchise alongside EXXUA™ for MDD.

Ownership category

akta.pro rank

Product category

CNS Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAF

Neurology & Psychiatry (CNS) Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Controlled-release pharmaceuticals
• Oral drug delivery
• ADHD medications
• CNS therapeutics
• Extended-release formulations

Headquarters

HQ city

Grand Prairie

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Distribution channels1 record

Marketing channels4 records

Core offering

Neos Therapeutics is an oral drug delivery company that develops controlled time-release pharmaceutical technologies. It focuses on central nervous system (CNS) and psychiatric conditions, particularly ADHD, with a portfolio of extended-release medications sold through a direct-to-patient and healthcare provider distribution model. The company is now a subsidiary of Aytu BioPharma following its 2021 acquisition.

Product overview

Aytu BioPharma is a pharmaceutical company offering a focused portfolio of CNS treatments. The product lineup includes EXXUA™ for major depressive disorder (MDD), an ADHD Portfolio for attention deficit/hyperactivity disorder, and a Pediatric Portfolio for younger patients. These novel therapeutics are complemented by patient support programs, with the company positioning itself around innovative medicines and bold actions in the psychiatric and CNS space.

Differentiator

Problem solved

Functional benefit

Brands

• EXXUA: Product for major depressive disorder (MDD)

Products and services

• ADHD Portfolio

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Supernus Pharmaceuticals: Specialty CNS pharma focused on ADHD, epilepsy, and depression. Direct peer as both companies develop differentiated CNS therapeutics targeting similar prescriber bases, with comparable scale and commercial strategy.
• Tris Pharma: Specialty pharma with proprietary oral drug delivery platforms and a strong ADHD portfolio including extended-release and orally disintegrating formulations. Closest direct competitor to Neos's technology-driven ADHD franchise.
• Ironshore Therapeutics: CNS specialty pharma focused on ADHD and related disorders, with proprietary once-daily ADHD therapies. Comparable as a focused CNS specialty player targeting the same prescriber and patient segments.
• Rhodes Pharmaceuticals: Specialty/generic pharma with a substantial ADHD stimulant portfolio. Comparable as a direct competitor in ADHD stimulants, competing on the same payer channels and prescriber base.
• Arbor Pharmaceuticals: Specialty pharma with CNS and ADHD products including a stimulant franchise. Comparable as a CNS specialty player with similar commercial scale and product overlap in ADHD.

Broad incumbents

• Takeda Pharmaceutical (Shire): Acquired Shire, the historical market leader in ADHD (Adderall, Vyvanse, Mydayis). Represents the dominant incumbent whose products and lifecycles shape the competitive environment for specialty ADHD players.
• Eli Lilly: Major pharma with Strattera (atomoxetine) and ongoing CNS pipeline activity. Broad incumbent in MDD/ADHD markets that defines treatment standards and competitive benchmarks.
• Teva Pharmaceutical: Largest generic manufacturer with significant ADHD stimulant generics (including authorized generics of Adderall). Broad incumbent whose pricing and supply decisions heavily influence specialty ADHD economics.
• Janssen Pharmaceuticals (Johnson & Johnson): Major pharma with Concerta (methylphenidate) franchise and broader CNS portfolio. Broad incumbent in ADHD and CNS, serving as a competitor and benchmark for product profile and lifecycle management.
• Pfizer: Large pharma with historical ADHD and CNS assets. Broad incumbent competitor whose strategic decisions in CNS affect the market opportunity for smaller specialty players.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/AytuBioPharma_
• Facebookfacebook.com/Aytu-BioPharma-1879831055582584
• LinkedInlinkedin.com/company/neos-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neos Therapeutics